A5021261473- Hepatitis C virus research
- Hepatitis B Virus Studies
- Liver Disease Diagnosis and Treatment
- HIV/AIDS drug development and treatment
- COVID-19 Clinical Research Studies
- Chronic Lymphocytic Leukemia Research
- SARS-CoV-2 detection and testing
- Cytomegalovirus and herpesvirus research
- SARS-CoV-2 and COVID-19 Research
- COVID-19 epidemiological studies
- Long-Term Effects of COVID-19
- Radiomics and Machine Learning in Medical Imaging
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Hepatocellular Carcinoma Treatment and Prognosis
- Thermal Regulation in Medicine
- Immune Cell Function and Interaction
- COVID-19 and healthcare impacts
- Lung Cancer Treatments and Mutations
- Cancer-related molecular mechanisms research
- Lung Cancer Diagnosis and Treatment
- MicroRNA in disease regulation
- Hepatitis Viruses Studies and Epidemiology
- Adrenal Hormones and Disorders
- Ferroptosis and cancer prognosis
- Immune responses and vaccinations
Guangzhou Eighth People's Hospital
2011-2025
Guangzhou Medical University
2017-2025
Twelfth Guangzhou City People's Hospital
2015
ABSTRACT We report temporal patterns of viral shedding in 94 laboratory-confirmed COVID-19 patients and modelled infectiousness profile from a separate sample 77 infector-infectee transmission pairs. observed the highest load throat swabs at time symptom onset, inferred that peaked on or before onset. estimated 44% could occur first symptoms index. Disease control measures should be adjusted to account for probable substantial pre-symptomatic transmission.
An amendment to this paper has been published and can be accessed via a link at the top of paper.
Abstract Background Antiviral therapies against the novel coronavirus SARS-CoV-2, which has caused a global pandemic of respiratory illness called COVID-19, are still lacking. Methods Our study ( NCT04252885 , named ELACOI), was an exploratory randomized (2:2:1) controlled trial assessing efficacy and safety lopinavir/ritonavir (LPV/r) or arbidol monotherapy for treating patients with mild/moderate COVID-19. Findings This successfully enrolled 86 COVID-19 34 randomly assigned to receive...
Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been redetected after discharge in some disease 2019 (COVID-19) patients. The reason for the recurrent positivity of test and potential public health concern due to this occurrence are still unknown. Here, we analyzed viral data clinical manifestations 289 domestic Chinese COVID-19 patients found that 21 individuals (7.3%) were readmitted hospitalization detection SARS-CoV-2 discharge. First, experimentally confirmed...
The clinical manifestations and factors associated with the severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections outside Wuhan are not clearly understood.All laboratory-confirmed cases SARS-Cov-2 infection who were hospitalized monitored in Guangzhou Eighth People's Hospital recruited from January 20 to February 10.A total 275 patients included this study. median patient age was 49 years, 63.6% had exposure Wuhan. virus incubation period 6 days. Fever (70.5%)...
Abstract To investigate the dynamic changes of Krebs von den Lungen‐6 (KL‐6) among patients with coronavirus disease 2019 (COVID‐19) and role KL‐6 as a noninvasive biomarker for predicting long‐term lung injury, clinical information laboratory tests 166 COVID‐19 were collected, correlation analysis between other parameters was conducted. There 17 (10.2%, 17/166) severe/critical 149 (89.8%, 149/166) mild in our cohort. Serum significantly higher than (median 898.0 vs. 451.2 U/ml, p <...
: Previous studies of coronavirus disease 2019 (COVID-19) were mainly focused on cross-sectional analysis. In this study, we sought to evaluate the dynamic changes immunological and radiographic features, association with outcome pulmonary lesions in COVID-19 patients.
Background and AimsLarge-scale data on the hepatitis D virus (HDV)/hepatitis B (HBV) co-infection rate is needed to estimate current epidemiology of HDV in China. This study aimed HDV.
Human pegivirus type 2 (HPgV-2) is a novel blood-borne human that mainly infects hepatitis C virus (HCV)-infected subjects. We have investigated the prevalence of HPgV-2 in China, its association with HCV and immunodeficiency 1 (HIV-1), impact on viral load liver damage.A cross-sectional study was conducted both blood donors HCV- HIV-1-infected patients Guangzhou, China. All subjects were screened for anti-HPgV-2 RNA. Demographic clinical information obtained from electronic medical...
Suppressor of cytokine signaling 1 (SOCS1) has long been thought to block type I interferon signaling. However, IFN-λ, a III IFN with limited receptor expression in hepatic cells, efficiently inhibits HCV (Hepatitis C virus) replication vivo potentially less side effects than IFN-α. Previous studies demonstrated that and activated Janus kinase/signal transducer activator transcription (Jak/STAT) pathway differently, delayed but prolonged activation by IFN-λ stimulation compared IFNα/β. the...
Abstract Chronic hepatitis B virus (HBV) infection (CHB) in children remains a public health challenge despite significant success programme is established to prevent mother‐to‐child transmission. In particular, CHB Chinese are mostly acquired through vertical transmission, which differs from the common route reported other countries and regions. This situation has resulted high endemic prevalence of adults. Thus, successful treatment with will development advanced liver diseases late...
Background and Aims: Ravidasvir (RDV) is a new generation pangenotypic hepatitis C virus (HCV) NS5A inhibitor, with high barrier to baseline resistance-associated species. This the first phase 2/3 study conducted in Mainland China confirming efficacy safety of RDV + ritonavir-boosted danoprevir ribavirin for 12 weeks treatment-naïve noncirrhotic patients genotype 1 infection large population. Methods: In this multicenter, randomized, double-blinded, placebo-controlled trial (NCT03362814), we...
An affordable, pangenotypic regimen remains as an unmet medical need for chronic hepatitis C patients in China. This single-arm, open-label, multicenter, phase 3 trial evaluated the efficacy and safety of coblopasvir, a non-structural protein 5A (NS5A) inhibitor, combined with sofosbuvir treating Chinese virus (HCV) infection.
Calcitriol, the bioactive metabolite of vitamin D, was reported to inhibit HCV production in a synergistic fashion with interferon, treatment vitro . Our previous study established that miR‐130a inhibits replication by restoring host innate immune response. We aimed determine whether there is additive inhibitory effect calcitriol and on replication. Here we showed potentiates anti‐HCV both Con1b replicon J6/JFH1 culture systems. Intriguingly, this potentiating not through upregulating...
Background and Aims: Genotype (GT) 1 remains the predominant hepatitis c virus (HCV) GT in Chinese patients. Over 80% of those patients harbor interferon-sensitive CC allele IFNL4rs12979860, which is favorable for interferon-based treatment regimens. This phase III clinical trial aimed to evaluate efficacy safety ritonavir-boosted danoprevir plus pegylated-interferon α-2a ribavirin regimen 12 weeks treatment-naïve mainland infected with HCV GT1 without cirrhosis. Methods: One hundred...
Coronavirus Disease 2019 (COVID-19) is threatening billions of people. We described the clinical characteristics and explore virological immunological factors associated with outcomes.297 COVID-19 patients hospitalized in Guangzhou Eighth People's Hospital between January 20 February 20, 2020 were included. Epidemiological, laboratory data collected analyzed. Severe Acute Respiratory Syndrome 2 (SARS-CoV-2) RNA respiratory tract, blood samples digestive tract was detected lymphocyte subsets...
A pan-genotypic and effective treatment regimen for patients with chronic hepatitis C virus (HCV) infection remains an unmet medical need in China. Alfosbuvir is a novel potent HCV NS5B polymerase inhibitor development the of infection. We conducted phase 3 study to evaluate efficacy safety alfosbuvir combination daclatasvir Chinese All received 600 mg tablets plus 60 once daily 12 weeks. The primary endpoint was sustained virological response weeks after end (SVR12). follow-up visit done at...
A simple, pangenotypic and effective treatment regimen for patients with a broad range of chronic hepatitis C virus (HCV) infections remains an unmet medical need. We conducted phase 2, randomized, open study involving untreated HCV genotypes 1, 3, or 6 infections. Patients without cirrhosis were randomly assigned in 1:2 ratio to receive capsules the NS5A inhibitor coblopasvir at dose 30 60 mg plus tablets nucleotide polymerase sofosbuvir (400 mg) once daily 12 weeks. received The primary...
Objective: To quantify emphysema and air trapping at inspiratory expiratory phase multi-slice spiral CT(MSCT) scanning in smokers without respiratory symptoms, analyze the correlation between CT quantifiable parameters lung function parameters. Methods: A total of 72 smokers, who underwent medical examinations from September 2013 to 2016 Changzheng Hospital were enrolled this research divided into two groups: 24 with COPD 48 COPD.Besides, thirty-nine non-smokers normal pulmonary as...
Alfosbuvir is a novel potent HCV NS5B polymerase inhibitor in development for the treatment of chronic infection. Our previous studies indicated that alfosbuvir monotherapy was well-tolerated and druggable healthy subjects HCV-infected patients. Here, we evaluate efficacy safety combination with daclatasvir Chinese patients genotype 1, 2, 3 or 6. In this open-label study, infection were randomly assigned 1:1:1 ratio to receive 12 weeks 60 mg plus at dose 400, 600 800 (Cohort A, B C) daily....
Abstract The data on direct‐acting antivirals (DAAs) in chronic hepatitis C (CHC) patients southern China with multiple genotypes circulating are limited. This study aims to evaluate the efficacy and safety of DAA regimens among CHC Guangdong, China. A total 220 receiving a variety were enrolled. primary outcome was sustained virologic response (SVR) at 12 weeks. Resistance associated substitutions (RASs) evaluated by deep sequencing. overall SVR rate 96.4%, 97.7% for genotype 1, 100% 2,...
Objective: To understand the effectiveness and safety sofosbuvir/velpatasvir (SOF/VEL) combination ±ribavirin in treatment of chronic hepatitis C virus (HCV) infection China. Methods: A total 96 Chinese adults with HCV who were treated SOF/VEL ± ribavirin for 12 weeks between July 2018 February 2020 selected. RNA, routine blood test, liver, kidney coagulation function, abdominal Color Doppler ultrasound or CT liver stiffness detected at baseline, 4 treatment, end follow-up. Adverse events...